This is an open-label, multicenter, FIH, phase 1/2 trial to assess safety, tolerability, immunogenicity, and preliminary efficacy of the microbial-derived therapeutic vaccine EO4010 in combination with nivolumab for treatment of patients with unresectable, previously treated, metastatic colorectal cancer
Open-label multicenter study